# A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study

> **NCT06149104** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** sacubitril/valsartan

## Key facts

- **NCT ID:** NCT06149104
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-04
- **Primary completion:** 2024-08-14
- **Final completion:** 2024-08-14
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06149104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06149104, "A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06149104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*